Atopic dermatitis (AD) is a chronic inflammatory skin disease with pruritus, characterized by
recurrent eczema with exacerbations and remissions. AD impairs patients' QOL and places …

Atopic dermatitis (AD) is a chronic, inflammatory skin disorder that most frequently occurs in
children, but it can also affect adults. Even though most AD cases can be managed with …

Background Tralokinumab, a fully human IgG4 monoclonal antibody that specifically binds
with high affinity to interleukin‐13, effectively reduces moderate‐to‐severe atopic dermatitis …

Atopic dermatitis (AD) is a common, heterogeneous, inflammatory skin disorder
characterized by chronic or relapsing eczematous lesions with intense pruritus and …

Atopic dermatitis (AD) is a common chronic inflammatory skin condition that has a significant
impact on a patient's quality of life and requires ongoing management. Conventional topical …

Background Atopic dermatitis (AD) is one of the most common chronic inflammatory skin
diseases worldwide. AD pathogenesis is multifactorial, involving environmental and genetic …

Abrocitinib, an oral once‐daily Janus kinase 1 selective inhibitor, is under development for
the treatment of atopic dermatitis. This phase 1, nonrandomized, open‐label, single‐dose …

Dupilumab is a dual inhibitor of interleukin-4 and interleukin-13 and is mainly used to treat
moderate-to-severe atopic dermatitis. Post-marketing safety data related to dupilumab have …

Dupilumab, a monoclonal antibody against the common receptor of interleukin (IL)-4 and IL-
13, was the first biologic therapy approved in Canada for treatment of moderate-to-severe …

Background: Dupilumab, an interleukin (IL)-4 receptor-α inhibitor that blocks IL-4 and IL-13
signaling pathways, is an effective and well-tolerated therapy for moderate-to-severe atopic …